An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Reads0
Chats0
TLDR
The standard of care (SOC) therapy for patients with chronic hepatitis C virus (HCV) infection has been the use of both peginterferon (PegIFN) and ribavirin (RBV) as mentioned in this paper.About:
This article is published in Hepatology.The article was published on 2011-10-01 and is currently open access. It has received 1117 citations till now. The article focuses on the topics: Boceprevir & Telaprevir.read more
Citations
More filters
Journal ArticleDOI
Hepatocyte Nuclear Factor 4α and Downstream Secreted Phospholipase A2 GXIIB Regulate Production of Infectious Hepatitis C Virus
TL;DR: The results suggest that HNF4α and its downstream PLA2GXIIB are important factors affecting the late stage of the HCV life cycle and may serve as potential drug targets for the treatment of HCV infection.
Journal ArticleDOI
Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection
Lauren Fusfeld,Jyoti Aggarwal,Carly Dougher,Montserrat Vera-Llonch,Stephen Bubb,Mrudula Donepudi,Thomas F. Goss +6 more
TL;DR: Understanding challenges and expectations from patients is important in identifying opportunities for education to optimize patient adherence to their HCV treatment regimen.
Journal ArticleDOI
Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors
Eva Rivero-Buceta,Paula Carrero,Elisa G. Doyagüez,Andrés Madrona,Ernesto Quesada,María-José Camarasa,María-Jesús Pérez-Pérez,Pieter Leyssen,Jan Paeshuyse,Jan Balzarini,Johan Neyts,Ana San-Félix +11 more
TL;DR: It is demonstrated that the 2,3, 4-trihydroxybenzoyl moiety provides better antiviral activities than the galloyl (3,4,5-triHydroxybenZoyl) moiety that is present in natural green tea catechins.
Journal ArticleDOI
Discontinued drugs in 2012 – 2013: hepatitis C virus infection
TL;DR: Learning from HCV drug development failures will help pharmaceutical companies and researchers to develop better strategies for the future, for example, by reporting the candidate drugs that were discontinued and the reason for discontinuation.
Journal ArticleDOI
New Pharmacotherapy for Hepatitis C
David N. Assis,J K Lim +1 more
TL;DR: Newer classes targeting the hepatitis C virus (HCV) protease, polymerase, NS5A, and other components of the viral genome demonstrate great promise to further enhance viral eradication with superior efficacy, improved tolerability, shorter duration of therapy, and diminished requirement for interferon.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Dongliang Ge,Jacques Fellay,Alexander J. Thompson,Jason Simon,Kevin V. Shianna,Thomas J. Urban,Erin L. Heinzen,Ping Qiu,Arthur H. Bertelsen,Andrew J. Muir,Mark S. Sulkowski,John G. McHutchison,David Goldstein +12 more
TL;DR: It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more
TL;DR: Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
Related Papers (5)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more